PCM
EVH icon

Peregrine Capital Management’s Evolent Health EVH Stock Holding History

Peregrine Capital Management’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-737,977
Closed -$2.95M – 303
2025
Q4 		$2.95M Sell
737,977
-15,076
-2% -$83.8K 0.09% 241
2025
Q3 		$6.37M Buy
753,053
+50,015
+7% +$485K 0.19% 150
2025
Q2 		$7.92M Buy
703,038
+181,980
+35% +$1.67M 0.24% 121
2025
Q1 		$4.93M Buy
521,058
+17,457
+3% +$176K 0.16% 199
2024
Q4 		$5.67M Buy
503,601
+198,358
+65% +$3.49M 0.17% 201
2024
Q3 		$8.63M Sell
305,243
-32,541
-10% -$839K 0.26% 94
2024
Q2 		$6.46M Buy
337,784
+34,156
+11% +$872K 0.19% 190
2024
Q1 		$9.96M Sell
303,628
-2,930
-1% -$93.5K 0.29% 79
2023
Q4 		$10.1M Sell
306,558
-52,230
-15% -$1.48M 0.3% 75
2023
Q3 		$9.77M Buy
358,788
+12,973
+4% +$361K 0.29% 105
2023
Q2 		$10.5M Buy
345,815
+30,939
+10% +$1M 0.29% 113
2023
Q1 		$10.2M Sell
314,876
-24,236
-7% -$766K 0.29% 123
2022
Q4 		$9.52M Buy
339,112
+17,972
+6% +$515K 0.3% 143
2022
Q3 		$11.5M Sell
321,140
-96,298
-23% -$3.39M 0.37% 79
2022
Q2 		$12.8M Sell
417,438
-247
-0.1% -$7.2K 0.39% 75
2022
Q1 		$13.5M Sell
417,685
-72,557
-15% -$1.9M 0.32% 96
2021
Q4 		$13.6M Buy
490,242
+52,418
+12% +$1.5M 0.27% 115
2021
Q3 		$13.6M Sell
437,824
-276,387
-39% -$6.64M 0.28% 127
2021
Q2 		$15.1M Sell
714,211
-37,672
-5% -$755K 0.27% 159
2021
Q1 		$15.2M Sell
751,883
-103,952
-12% -$1.98M 0.28% 166
2020
Q4 		$13.7M Sell
855,835
-77,451
-8% -$1.02M 0.26% 181
2020
Q3 		$11.6M Sell
933,286
-232,870
-20% -$2.74M 0.31% 120
2020
Q2 		$8.3M Sell
1,166,156
-38,825
-3% -$260K 0.24% 144
2020
Q1 		$6.54M Buy
1,204,981
+15,862
+1% +$142K 0.23% 137
2019
Q4 		$10.8M Sell
1,189,119
-341,644
-22% -$2.78M 0.27% 139
2019
Q3 		$11M Buy
1,530,763
+405,993
+36% +$2.91M 0.3% 133
2019
Q2 		$8.94M Sell
1,124,770
-3,214
-0.3% -$38.1K 0.22% 174
2019
Q1 		$14.2M Buy
1,127,984
+175,889
+18% +$2.78M 0.36% 128
2018
Q4 		$19M Buy
952,095
+81,168
+9% +$1.88M 0.54% 65
2018
Q3 		$24.7M Sell
870,927
-80,489
-8% -$1.92M 0.59% 63
2018
Q2 		$20M Sell
951,416
-428,231
-31% -$8.11M 0.5% 79
2018
Q1 		$19.7M Sell
1,379,647
-228,233
-14% -$3.27M 0.48% 79
2017
Q4 		$19.8M Buy
1,607,880
+125,102
+8% +$1.76M 0.47% 75
2017
Q3 		$26.4M Buy
1,482,778
+495,536
+50% +$10.2M 0.63% 44
2017
Q2 		$25M Sell
987,242
-112,358
-10% -$2.7M 0.62% 44
2017
Q1 		$22.9M Sell
1,099,600
-174,776
-14% -$3.35M 0.58% 54
2016
Q4 		$18.9M Buy
1,274,376
+206,364
+19% +$4.07M 0.49% 67
2016
Q3 		$26.3M Buy
+1,068,012
New +$25M 0.69% 33

Other funds holding EVH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RF
Rubicon Founders Nashville, Tennessee $138M AUM 61.96% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Peregrine Capital Management's EVH Position: Q1 2026 in Review

Peregrine Capital Management sold out of Evolent Health (EVH) in Q1 2026, closing a stake of 737,977 shares — an estimated $2.95M sold.

Peregrine Capital Management first reported a position in EVH in Q3 2016 and held it in 38 quarters. The position peaked at $26.4M in Q3 2017. 191 funds tracked by Wall St. Rank hold EVH as of Q1 2026.

  • Peregrine Capital Management reported no remaining Evolent Health position as of Q1 2026 after selling out during the quarter.
  • Peregrine Capital Management sold 737,977 Evolent Health shares in Q1 2026, an estimated $2.95M.
  • Peregrine Capital Management first reported a position in Evolent Health in Q3 2016 and held it in 38 quarters.
  • Peregrine Capital Management's Evolent Health position peaked at $26.4M in Q3 2017.
  • 191 funds tracked by Wall St. Rank held Evolent Health as of Q1 2026.

Based on Peregrine Capital Management's 13F filing for Q1 2026, filed 23 Apr 2026.